Phase 2b SunRISe-1 data showed TAR-200 monotherapy achieved an 82.4% complete response rate in BCG-unresponsive, high-risk ...

Discrepancies between clinical and pathologic staging of muscle-invasive bladder cancer (MIBC) are found in three-quarters of patients following radical cystectomy without neoadjuvant therapy, ...

BOND-003 evaluated the efficacy and safety of cretostimogene grenadenorepvec, an oncolytic immunotherapy, in patients with carcinoma in situ BCG-unresponsive NMIBC.

CG Oncology, Inc. (CGON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings ...

Recurrence in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer is common, and there have been a lack of alternative treatments to TURBT.

We recently published an article titled Why Traders Flocked to These 10 Stocks on Monday. In this article, we are going to ...

Shares of CG Oncology catapulted Monday after the biotech unveiled promising results for a J&J-rivaling bladder cancer ...

CG Oncology, Inc. (NASDAQ: CGON) has recently announced promising results for cretostimogene grenadenorepvec monotherapy at the 2025 American Urological Association (AUA) Annual Meeting. The phase 3 ...

Biohaven's $600M financing deal, Protara's cell therapy data, Pfizer's bladder cancer success, plus news from CG Oncology, ...

CG Oncology shares rose Monday after the company shared positive data from a study of its bladder-cancer treatment. The stock gained 39% to $31.10 in premarket trading.

Shares of CG Oncology Inc. gained 25% April 28 on the back of phase III data presented at the American Urological Association meeting over the weekend showing its cretostimogene grenadenorepvec ...

With an FDA review underway, Johnson & Johnson is aiming to “fundamentally change” how bladder cancer is treated. | With an ...